Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 13 January 2026 - 14 January 2026

FTSE 100 climbs on miners and AstraZeneca as record gold keeps UK stocks in play

FTSE 100 climbs on miners and AstraZeneca as record gold keeps UK stocks in play

London, Jan 14, 2026, 10:58 GMT — Regular session Britain’s FTSE 100 rose 0.3% to 10,170.81 in mid-morning trade, helped by gold-linked miners and a lift in AstraZeneca. Endeavour Mining gained 3.4%, AstraZeneca rose 2.6% and Glencore added 2.3%, while the index came into the day after edging down 0.03% on Tuesday. (Hargreaves Lansdown) The tone matters now because the…
14 January 2026
····
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next

Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next

New York, Jan 14, 2026, 05:46 EST — Premarket Viatris Inc shares showed little movement in premarket trading Wednesday, following a more than 5% jump the day before. The stock was indicated near $13.37. The J.P. Morgan Healthcare Conference holds weight because it can quickly change the sector’s mood, particularly for mid-cap firms where a single comment from management can…
14 January 2026
····
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

London, Jan 14, 2026, 09:03 GMT — Regular session GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination. (MarketScreener) The move lands as investors look for signposts on how much growth GSK can squeeze from its oncology pipeline before it…
14 January 2026
····
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

New York, Jan 13, 2026, 18:23 EST — After-hours Eli Lilly and Company shares were down 0.4% at $1,077.19 in after-hours trading on Tuesday. The U.S. Food and Drug Administration asked drugmakers to remove suicide-related warnings from labels of GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — including Lilly’s Zepbound. (Reuters) The label shift…
14 January 2026
···
KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

New York, Jan 13, 2026, 16:15 EST — After-hours Kiniksa Pharmaceuticals International, plc saw its shares drop 6.1% to $38.61 on Tuesday, following the release of updated revenue forecasts for its key drug ARCALYST. The stock briefly dipped to an intraday low of $38.27. Yahoo Finance The move matters because ARCALYST is carrying the load: it serves as the company’s…
13 January 2026
····
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as…
13 January 2026
···
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

New York, January 13, 2026, 14:17 (EST) — Regular session Shares of Travere Therapeutics (TVTX.O) dropped 19% to $27.56 in early afternoon trading Tuesday after the U.S. Food and Drug Administration extended its review of the kidney drug Filspari for broader use. The stock had fallen as much as 34% earlier, hitting a low of $22.35. (Reuters) The delay comes…
13 January 2026
···
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

NEW YORK, Jan 13, 2026, 12:18 EST — Regular session Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech. (Reuters) This shift is significant as major drugmakers ramp up their push for obesity pills.…
13 January 2026
····
Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

New York, Jan 13, 2026, 12:12 EST — Regular session Johnson & Johnson shares climbed roughly 1.6% to $212.98 on Tuesday, bucking a minor slide in healthcare stocks as the overall market showed little direction. The stock hit a session peak of $213.48 and dipped to $208.93 at its low. Meanwhile, the Health Care Select Sector SPDR ETF fell around…
13 January 2026
···
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

New York, Jan 13, 2026, 11:51 EST — Regular session Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration’s request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo…
13 January 2026
···
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

New York, Jan 13, 2026, 10:50 (EST) — Regular session Pfizer Inc (PFE) shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase…
13 January 2026
··
Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

New York, Jan 12, 2026, 21:31 EST — The market has closed. Merck & Co boosted its long-term revenue forecast for several new products and pipeline candidates, projecting $70 billion from these “new growth drivers” by the mid-2030s. The company raised its cardiometabolic and respiratory sales outlook to around $20 billion, up from $15 billion, while its infectious-disease forecast jumped…
13 January 2026
···
1 … 4 5 6 7 8 … 45

Stock Market Today

  • CF Industries Shares Surpass Analyst Target Price Amid Positive Outlook
    January 22, 2026, 8:18 AM EST. Shares of CF Industries Holdings Inc (CF) recently climbed above the average analyst 12-month target price of $68.65, reaching $71.73. This move prompts analysts to reconsider valuations, possibly adjusting target prices higher if company fundamentals remain strong. Ten analyst estimates contribute to the $68.65 average, ranging from $59.50 to $83.00, with a standard deviation of $7.39. Analyst sentiment remains bullish, with six current strong buy ratings and no sell ratings. Investors are urged to reevaluate CF's valuation and growth prospects as the stock surpasses consensus targets, signaling potential for further gains in the fertilizer company's shares.
Go toTop